Ajinomoto: Forge‘s customer quality upgrade and the path the US Healthcare profitability
Ajinomoto's US Healthcare business is splitting from a cost center to a profit engine—and the market hasn't priced it. Forge's customer pipeline has doubled in 12 months (4 new phase 1-2 trials vs 2 in FY3/25), while the division is on track for 34% YoY revenue growth to ¥87.8b.
Institutional-grade analysis used by equity desks before repricing events. 18 pages.
Report fact snapshot
- Publisher
- Bernstein
- Date
- 2026-06-25
- Type
- Company Report
- Region
- United States, Asia Pacific
- Companies
- BP, Target, Food, Ajinomoto
- Key signal
- ¥87.8
The market assumes Ajinomoto's US Healthcare division is a low-margin CDMO with limited near-term profitability.
Data shows Forge's customer pipeline has doubled in quality (4 new phase 1-2 trials in 12 months vs 2 in FY3/25), driving 34% YoY revenue growth to ¥87.8b and a path to break-even by H1 FY3/27.
Ajinomoto's valuation should re-rate as the market recognizes Forge's structural margin expansion from higher-quality customers.
Based on Bernstein research, June 2026 data and regional breakdowns
Key Signals
Ajinomoto's US Healthcare division is undergoing a structural revenue acceleration, but the market still prices it as a slow-growth CDMO.
US Healthcare revenue is forecast to grow 34% YoY to ¥87.8b in FY3/27, versus the company's own 27% growth target. The stock trades at ¥5,480 with a ¥7,100 target (30% upside).
Why it matters: Identifies the exact point where consensus models diverge from actual data—the market underestimates Forge's customer quality upgrade and its impact on revenue growth and break-even timing.
Forge is expected to reach break-even by H1 FY3/27, with the Skylark contract incremental to Ajinomoto's guidance.
Bernstein expects Forge to reach break-even by half year FY3/27. Skylark Bio's phase 1-2 trial is expected from Q2 FY3/27.
Why it matters: Frames the catalyst window before violent repricing begins—Forge's break-even announcement in H1 FY3/27 will force the market to re-rate the entire US Healthcare division.
Forge's customer pipeline has doubled in quality, with four new phase 1-2 trials and one phase 3 trial starting in the last 12 months.
4 Forge customers started phase 1-2 trials and 1 moved to phase 3 in the last 12 months, compared to only 2 companies entering clinical trials during FY3/25.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus—Forge's customer quality upgrade is a leading indicator of revenue acceleration.
What You Gain From This Report
Decision Insight
The mispricing reveals that Ajinomoto's US Healthcare division is structurally undervalued relative to its revenue acceleration and margin expansion trajectory.
Missed Risk
Missing this mispricing means missing a 30% re-rating as the market reprices Forge's customer quality upgrade and break-even path.
Timing Advantage
Acting now captures the catalyst window before Forge's break-even announcement and Skylark contract details force consensus upgrades.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Consensus models price Ajinomoto as a legacy food company, ignoring the structural revenue acceleration in US Healthcare to 34% YoY growth.
Capital should rotate into Ajinomoto as Forge's customer quality upgrade drives margin expansion and break-even by H1 FY3/27.
The Skylark contract and Forge break-even announcement in the next 6 months will close the mispricing gap before the market reprices.
Report Summary
The market treats Ajinomoto's US Healthcare division as a low-margin CDMO, but Forge's customer quality upgrade is driving revenue acceleration and a clear path to break-even. This structural shift remains unpriced, creating a re-rating opportunity.
Institutional Content Below
Full broker analysis includes detailed valuation models, price target logic (¥7,100), Forge's customer pipeline breakdown, and US Healthcare revenue forecasts through FY3/29. Charts and assumptions are locked in the full report.
Key Takeaways
- Customer Quality Upgrade: Forge added 4 new phase 1-2 clinical trial customers in the last 12 months, compared to only 2 in all of FY3/25, signaling a step-change in pipeline quality.
- Revenue Outperformance: US Healthcare revenue is forecast to reach ¥87.8b in FY3/27, growing 34% YoY and exceeding the company's own 27% growth target.
- Break-even Catalyst: Forge is expected to reach break-even by H1 FY3/27, with the Skylark Bio contract incremental to guidance, forcing a market re-rating.
- Valuation Re-rating: The stock trades at ¥5,480 with a ¥7,100 target (30% upside), yet the market has not priced the revenue acceleration from higher-quality customers.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Bernstein Ajinomoto report. It helps users review Ajinomoto: Forge‘s customer quality upgrade and the path the US Healthcare profitability coverage, key takeaways, and related broker or sector research paths across Healthcare, Ajinomoto:, Forge‘s; BP, Target.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.